IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Regulus; Sanofi-Aventis; and More

Feb 16, 2012

Premium

Title: Method and Medicament for Inhibiting the Expression of a Given Gene

Patent Number: 8,114,851

Filed: Oct. 31, 2007

Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Drive Away the Flies

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

Fewer Transfusions Needed

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Alteration Here and There to Win

Futurism writes that gene doping could be the next generation of cheating in sports.

This Week in Nature

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Featured White Papers

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

Main menu